[REVISION HISTORY]

Molbio Diagnostics IPO and market listing

Updated 2 times since CLSTR started tracking revisions of this situation.

What changed

2026-08-11 12:51 UTC → 2026-08-17 08:33 UTC · added ~~removed~~

Molbio Diagnostics IPO ~~process~~ and market listing

Molbio Diagnostics, a point-of-care diagnostics firm, secured approximately Rs 281.5 crore from anchor investors ahead of its initial public offering (IPO). The company allocated 34.88 lakh equity shares to 33 ~~investors~~ investors, including Goldman Sachs, BlackRock Global Funds, and Tata Mutual Fund, at the top of its price ~~band, which is set between~~ band of Rs 768 ~~and~~ to Rs 807 per share. The ~~IPO includes~~ IPO, which opened for public subscription on August 10 and closed on August 12, consists of a fresh issue of up to Rs 200 crore and an offer-for-sale of up to 91.66 lakh shares. At the upper price band, the post-issue valuation was projected at approximately Rs 9,300 crore. Proceeds are ~~intended~~ earmarked for ~~research and development,~~ a Rs 106 crore R&D centre, the expansion of ~~its~~ the Truenat platform, and ~~capital expenditures~~ Rs 72 crore for plant and equipment at manufacturing units in Goa and Visakhapatnam. ~~On August 10,~~ Despite a sluggish broader market influenced by geopolitical tensions and foreign institutional investor outflows, Molbio Diagnostics ~~launched its Rs 940-crore IPO. This launch occurs amidst~~ saw a ~~broader surge in~~ successful listing on the ~~Indian primary market, where several major firms are collectively seeking to raise approximately~~ BSE and NSE. The stock listed at Rs ~~7,443 crore. While high liquidity is driving investor appetite, market experts have advised caution regarding stretched valuations.~~ 980, significantly higher than its issue price of Rs 807.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.